UNSPSC 51401563: Diazepam hydrochloride

This classification denotes a benzodiazepine with the molecular formula C16H13CLN2O.CLH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 6JD21U639H. European Medicines Agency schedules diazepam hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB32951. Most nations, for tariff and trade purposes, schedule diazepam hydrochloride under HS 29339190. As of Q4 2014, DIAZEPAM HYDROCHLORIDE remains US FDA's Preferred Term for this commodity.

Diazepam hydrochloride bears US NLM identifiers UMLS ID C3273839 and NCI Concept Code C98133. SMILES: CN1C2CCC(CC2C(=NCC1=O)C3CCCCC3)CL.CL.

UNSPSC 51401563 Diazepam hydrochloride is a Commodity code that classifies pharmaceutical active ingredients and finished pharmaceutical products procured by state and local health agencies, corrections departments, and cooperative purchasing alliances. State and local governments buy under this code to stock community health facilities, support addiction-treatment and emergency-response initiatives, and supply institutional health systems through group purchasing arrangements. Recent solicitations show demand for finished pharmaceutical products—including naloxone (an opioid antagonist procured alongside drug deactivation systems) and generic multi-source pharmaceuticals distributed through authorized pharmaceutical wholesalers—rather than bulk active pharmaceutical ingredients alone. Issuing bodies include county health departments (Seminole County, Florida), state health and human services agencies (Texas HHS Commission), and multistate cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance, or MMCAP, serving multiple state and local government participants).

Recent activity spans Florida, Texas, and Minnesota. Seminole County, Florida issued IFB 60459723LAS on June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries and a response deadline of July 26, 2023. The Texas Health and Human Services Commission posted RFI HHS0017013 on April 3, 2026, to gather market intelligence on direct-to-manufacturer prescription programs that could bypass traditional pharmacy benefit managers and wholesalers. MMCAP issued RFP S1070000015802 on January 20, 2026, for generic multi-source pharmaceuticals and OTC products to be distributed across participating state and local government facilities in Minnesota and Oregon, with proposals due March 26, 2026, and contract awards effective July 1, 2026; vendors must maintain relationships with authorized wholesalers (AmerisourceBergen, Cardinal Health, and Morris & Dickson) and comply with cGMP and Drug Supply Chain Security Act requirements.